Letter
Medicine, General & Internal
Kurt Stoschitzky
Summary: In the SECURE trial, it was found that the use of a polypill containing aspirin, ramipril, and atorvastatin significantly reduced the risk of cardiovascular events in older patients with recent myocardial infarction. However, the absence of beta-blockers in this polypill raised questions as these drugs have been known to be effective after myocardial infarction and are recommended in current guidelines.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Jose M. Castellano, Stuart J. Pocock, Deepak L. Bhatt, Antonio J. Quesada, Ruth Owen, Antonio Fernandez-Ortiz, Pedro L. Sanchez, Francisco Marin Ortuno, Jose M. Vazquez Rodriguez, Alexandra Domingo-Fernandez, Inigo Lozano, Maria C. Roncaglioni, Marta Baviera, Andreana Foresta, Luisa Ojeda-Fernandez, Furio Colivicchi, Stefania A. Di Fusco, Wolfram Doehner, Antje Meyer, Francois Schiele, Fiona Ecarnot, Ales Linhart, Jean-Claude Lubanda, Gregory Barczi, Bela Merkely, Piotr Ponikowski, Marta Kasprzak, Juan M. Fernandez Alvira, Vicente Andres, Hector Bueno, Timothy Collier, Frans Van de Werf, Pablo Perel, Moises Rodriguez-Manero, Angeles Alonso Garcia, Marco Proietti, Mikkel M. Schoos, Tabassome Simon, Jose Fernandez Ferro, Nicolas Lopez, Ettore Beghi, Yannick Bejot, David Vivas, Alberto Cordero, Borja Ibanez, Valentin Fuster
Summary: The study showed that taking a polypill containing aspirin, ramipril, and atorvastatin within 6 months after myocardial infarction significantly reduced the risk of major adverse cardiovascular events compared to usual care.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Andre Rivera, Bruno Campos, Stephanie Ceolin, Amanda Godoi, Everton Castanha, Carlos Alberto Campello Jorge, Rhanderson Cardoso
Summary: This study aimed to determine the impact of a polypill-based strategy (PBS) on therapeutic adherence and cardiovascular outcomes compared with usual care for secondary prevention of cardiovascular diseases (CVDs) through a systematic review and meta-analysis of randomized controlled trials (RCTs). The results showed that PBS significantly improved therapeutic adherence, systolic blood pressure (SBP), and LDL-cholesterol (LDL-C), and reduced cardiovascular mortality. Therefore, PBS may be considered as a preferred option for patients with pre-existing CVD.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2023)
Article
Medicine, General & Internal
A. Gonzalez-Dominguez, A. Duran, A. Hidalgo-Vega, V. Barrios
Summary: This study aimed to determine the cost-effectiveness of the CNIC-Polypill strategy compared with separate monocomponents for the secondary prevention of recurrent cardiovascular events in Spain. The results showed that the CNIC-Polypill strategy resulted in more life-years (LY) and quality-adjusted LY (QALY) gains at a lower cost compared with monocomponents. Thus, it is a cost-saving strategy for the Spanish National Healthcare System.
REVISTA CLINICA ESPANOLA
(2023)
Review
Multidisciplinary Sciences
Reza Jahangiri, Aziz Rezapour, Reza Malekzadeh, Alireza Olyaeemanesh, Gholamreza Roshandel, Seyed Abbas Motevalian
Summary: The polypill appears to be a cost-effective intervention for primary and secondary prevention of CVD, improving medication adherence and quality of life at a relatively low price.
Review
Medicine, General & Internal
Antonio Coca, Jose Maria Castellano, Miguel Camafort, Valentin Fuster
Summary: Triple therapy with lipid-lowering, antihypertensive, and antiplatelet agents can reduce the risk of recurrent cardiovascular events and mortality. However, the implementation of these treatments is low in primary and secondary prevention, mainly due to low adherence. Simplifying the treatment regimen through the use of a polypill has shown to improve adherence and control of multiple risk factors.
POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ
(2023)
Article
Cardiac & Cardiovascular Systems
Steven H. J. Hageman, Jannick A. N. Dorresteijn, Michiel L. Bots, Folkert W. Asselbergs, Jan Westerink, Miriam P. van der Meulen, Arend Mosterd, Frank L. J. Visseren, F. W. Asselbergs, H. M. Nathoe, G. J. de Borst, M. L. Bots, M. Geerlings, M. H. Emmelot, P. A. de Jong, T. Leiner, A. T. Lely, N. P. van der Kaaij, L. J. Kappelle, Y. M. Ruigrok, M. C. Verhaar, F. L. J. Visseren, J. Westerink
Summary: This study aimed to compare the cost-effectiveness of treatment strategies guided by predicted lifetime benefit versus risk factor levels in patients with symptomatic atherosclerotic disease. The results showed that treatment based on lifetime benefit led to more CVD-free life years and more events avoided compared to risk factor-based treatment, indicating it is a potentially effective and cost-effective strategy for reducing residual CVD risk in these patients.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2022)
Article
Multidisciplinary Sciences
Julien Castioni, Nazanin Abolhassani, Peter Vollenweider, Gerard Waeber, Pedro Marques-Vidal
Summary: A study in Switzerland found that a large fraction of the population is eligible for the polypill, but only one-third of them actually benefits from an equivalent, and this proportion did not change over time.
SCIENTIFIC REPORTS
(2021)
Article
Cardiac & Cardiovascular Systems
Lilian Grigorian-Shamagian, Klaus Edel, Maria Asuncion Esteve-Pastor, Alvaro Acena, Claudia Silva, Joana Delgado-Silva, Georges Ntaios, Eftychia Demerouti, Carlos Brotons
Summary: The main objective of cardiovascular disease prevention is to reduce morbidity and mortality. Using a cardiovascular polypill can help improve risk factor control, especially in patients with uncontrolled risk factors.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Article
Health Care Sciences & Services
Juan Cosin-Sales, Jose M. Murcia-Zaragoza, Hector O. Pereyra-Rico, Fernando de la Guia-Galipienso, Kurt Hermans, Gabriel Rubio
Summary: Patients treated with the CNIC cardiovascular polypill show higher satisfaction and better adherence compared to those treated with separate monocomponents. A significant number of patients receiving monocomponent treatment prefer switching to the polypill regime.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH
(2021)
Article
Cardiac & Cardiovascular Systems
Shahin Merat, Elham Jafari, Amir Reza Radmard, Masoud Khoshnia, Maryam Sharafkhah, Alireza Nateghi Baygi, Tom Marshall, Abolfazl Shiravi Khuzani, Kar Keung Cheng, Hossein Poustchi, Reza Malekzadeh
Summary: Fixed-dose combination therapy is effective for preventing major cardiovascular events in individuals with and without presumed non-alcoholic steatohepatitis (pNASH). Among participants with fatty liver and elevated liver enzymes, the use of a polypill can reduce liver enzyme levels.
EUROPEAN HEART JOURNAL
(2022)
Article
Cardiac & Cardiovascular Systems
Roberto F. E. Pedretti, Dominique Hansen, Marco Ambrosetti, Maria Back, Thomas Berger, Mariana Cordeiro Ferreira, Veronique Cornelissen, Constantinos H. Davos, Wolfram Doehner, Carmen de Pablo Y. Zarzosa, Ines Frederix, Andrea Greco, Donata Kurpas, Matthias Michal, Elena Osto, Susanne Pedersen, Rita Esmeralda Salvador, Maria Simonenko, Patrizia Steca, David R. Thompson, Matthias Wilhelm, Ana Abreu
Summary: Optimal patient adherence to treatment is crucial for successful secondary prevention of cardiovascular disease (CVD). However, unsatisfactory adherence rates have been consistently observed for CVD risk factors and treatment. This consensus document provides a modern reappraisal of adherence to optimal treatment and offers simple, practical, and feasible suggestions to achieve this goal in the clinical setting, focusing on evidence-based concepts.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Jose R. Gonzalez-Juanatey, Alberto Cordero, Jose Ma Castellano, Luis Masana, Regina Dalmau, Emilio Ruiz, Antonio Sicras-Mainar, Valentin Fuster
Summary: This study suggests that treatment with the CNIC-Polypill in secondary prevention patients is associated with a significant reduction in the incidence of recurrent MACE, improved control rates for blood pressure and LDL cholesterol, and increased medication persistence compared to control groups.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2022)
Review
Cardiac & Cardiovascular Systems
Mohamed M. G. Mohamed, Mohammed Osman, Babikir Kheiri, Maryam Saleem, Alexandre Lacasse, Mohamad Alkhouli
Summary: This meta-analysis demonstrates that the use of polypills is significantly associated with reductions in blood pressure and blood lipid levels compared to standard of care, leading to a significant decrease in cardiovascular events.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2022)
Article
Geriatrics & Gerontology
Smita Nayak, Andrea Singer, Susan L. Greenspan
Summary: The study evaluated the cost-effectiveness of secondary fracture prevention intervention for Medicare beneficiaries, showing that the intervention was more effective and less expensive than usual care. It resulted in cost savings and increased quality-adjusted life-years, making it a recommended strategy for improving outcomes and reducing healthcare costs.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
(2021)
Article
Cardiac & Cardiovascular Systems
Alberto Cecconi, Jean Paul Vilchez-Tschischke, Jesus Mateo, Javier Sanchez-Gonzalez, Samuel Espana, Rodrigo Fernandez-Jimenez, Beatriz Lopez-Melgar, Leticia Fernandez Friera, Gonzalo J. Lopez-Martin, Valentin Fuster, Jesus Ruiz-Cabello, Borja Ibanez
Summary: The study found that colchicine may stabilize atherosclerotic plaque by reducing inflammatory activity and plaque burden, particularly in animals with high cholesterol levels.
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH
(2021)
Article
Health Care Sciences & Services
Claudia L. Leung, Mackenzie Naert, Benjamin Andama, Rae Dong, David Edelman, Carol Horowitz, Peninah Kiptoo, Simon Manyara, Winnie Matelong, Esther Matini, Violet Naanyu, Sarah Nyariki, Sonak Pastakia, Thomas Valente, Valentin Fuster, Gerald S. Bloomfield, Jemima Kamano, Rajesh Vedanthan
BMC HEALTH SERVICES RESEARCH
(2020)
Editorial Material
Cardiac & Cardiovascular Systems
Tomasz J. Guzik, Valentin Fuster
CARDIOVASCULAR RESEARCH
(2020)
Article
Cardiac & Cardiovascular Systems
Carlos Galan-Arriola, Rocio Villena-Gutierrez, Maria Higuero-Verdejo, Ivan A. Diaz-Rengifo, Gonzalo Pizarro, Gonzalo J. Lopez, Antonio de Molina-Iracheta, Claudia Perez-Martinez, Rodrigo D. Garcia, David Gonzalez-Calle, Manuel Lobo, Pedro L. Sanchez, Eduardo Oliver, Raul Cordoba, Valentin Fuster, Javier Sanchez-Gonzalez, Borja Ibanez
Summary: This study demonstrates that RIPC applied immediately before each doxorubicin injection can preserve cardiac contractility, result in significantly higher long-term left ventricular ejection fraction, and less cardiac fibrosis in a translatable large-animal model of AIC. RIPC is able to prevent mitochondrial fragmentation and dysregulated autophagy from AIC early stages, suggesting it as a promising intervention for testing in clinical trials for AIC.
CARDIOVASCULAR RESEARCH
(2021)
Editorial Material
Oncology
Carlos Cordon-Cardo, Elisabet Pujadas, Ania Wajnberg, Robert Sebra, Gopi Patel, Adolfo Firpo-Betancourt, Mary Fowkes, Emilia Sordillo, Alberto Paniz-Mondolfi, Jill Gregory, Florian Krammer, Viviana Simon, Luis Isola, Patrick Soon-Shiong, Judith A. Aberg, Valentin Fuster, David L. Reich
Editorial Material
Cardiac & Cardiovascular Systems
Samin K. Sharma, Valentin Fuster, Leonard Hofstra, Annapoorna S. Kini, Arthur Gianelli, Jagat Narula
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
(2021)
Article
Cardiac & Cardiovascular Systems
Mohit K. Turagam, Daniel Musikantow, Martin E. Goldman, Adel Bassily-Marcus, Edward Chu, Poojita Shivamurthy, Joshua Lampert, Iwanari Kawamura, Mahmoud Bokhari, William Whang, Benjamin Aaron Bier, Waqas Malick, Helen Hashemi, Marc A. Miller, Subbarao Choudry, Christopher Pumill, Tania Ruiz-Maya, Michael Hadley, Gennaro Giustino, Jacob S. Koruth, Noelle Langan, Aamir Sofi, Srinivas R. Dukkipati, Jonathan L. Halperin, Valentin Fuster, Roopa Kohli-Seth, Vivek Y. Reddy
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY
(2020)
Article
Urology & Nephrology
Lili Chan, Kumardeep Chaudhary, Aparna Saha, Kinsuk Chauhan, Akhil Vaid, Shan Zhao, Ishan Paranjpe, Sulaiman Somani, Felix Richter, Riccardo Miotto, Anuradha Lala, Arash Kia, Prem Timsina, Li Li, Robert Freeman, Rong Chen, Jagat Narula, Allan C. Just, Carol Horowitz, Zahi Fayad, Carlos Cordon-Cardo, Eric Schadt, Matthew A. Levin, David L. Reich, Valentin Fuster, Barbara Murphy, John C. He, Alexander W. Charney, Erwin P. Boettinger, Benjamin S. Glicksberg, Steven G. Coca, Girish N. Nadkarni
Summary: The study found that AKI is common among hospitalized COVID-19 patients in the United States, with a 46% occurrence rate and 19% of patients requiring dialysis. Independently predicting severe AKI were chronic kidney disease, male gender, and higher serum potassium levels at admission. In-hospital mortality was significantly higher in patients with AKI compared to those without AKI, with only 30% of AKI patients recovering kidney function by the time of discharge.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2021)
Article
Medicine, General & Internal
Kuniaki Takahashi, Patrick W. Serruys, Valentin Fuster, Michael E. Farkouh, John A. Spertus, David J. Cohen, Seung-Jung Park, Duk-Woo Park, Jung-Min Ahn, Arie Pieter Kappetein, Stuart J. Head, Daniel J. F. M. Thuijs, Yoshinobu Onuma, David M. Kent, Ewout W. Steyerberg, David van Klaveren
Article
Cardiac & Cardiovascular Systems
Rebeca Lorca, Marta Jimenez-Blanco, Jose Manuel Garcia-Ruiz, Gonzalo Pizarro, Rodrigo Fernandez-Jimenez, Ana Garcia-Alvarez, Leticia Fernandez-Friera, Manuel Lobo-Gonzalez, Valentin Fuster, Xavier Rossello, Borja Ibanez
Summary: This study assessed the transmural and lateral spread of myocardial damage in patients with acute myocardial infarction. It found that myocardial scarring decreased significantly in both the transmural and lateral dimensions 6 months after the event, indicating infarct resorption. The study also showed that myocardial salvage occurs in both transmural and lateral directions.
REVISTA ESPANOLA DE CARDIOLOGIA
(2021)
Article
Endocrinology & Metabolism
Odette Reifsnider, Anuraag Kansal, Pratik Pimple, Valerie Aponte-Ribero, Sarah Brand, Sharash Shetty
Summary: The study aimed to estimate the cost-effectiveness of using empagliflozin as a second-line treatment for type 2 diabetes patients with or without cardiovascular disease, compared to sitagliptin. The results showed that empagliflozin was cost-effective in the United States, leading to longer cardiovascular disease-free survival and reduced cardiovascular death compared to sitagliptin, with consistent findings across various analyses and scenarios. The study supports the adoption of guidelines by healthcare decision-makers for the treatment of type 2 diabetes patients.
DIABETES OBESITY & METABOLISM
(2021)
Article
Cardiac & Cardiovascular Systems
Carlos G. Santos-Gallego, Ariana P. Vargas-Delgado, Juan Antonio Requena-Ibanez, Alvaro Garcia-Ropero, Donna Mancini, Sean Pinney, Frank Macaluso, Samantha Sartori, Merce Roque, Fernando Sabatel-Perez, Anderly Rodriguez-Cordero, M. Urooj Zafar, Icilma Fergus, Farah Atallah-Lajam, Johanna P. Contreras, Cathleen Varley, Pedro R. Moreno, Vivian M. Abascal, Anuradha Lala, Ronald Tamler, Javier Sanz, Valentin Fuster, Juan J. Badimon
Summary: This study found that empagliflozin significantly improved left ventricular function and volumes, functional capacity, and quality of life in nondiabetic HFrEF patients, compared to placebo. The observations strongly support the role of sodium-glucose cotransporter 2 inhibitors in the treatment of HFrEF patients regardless of their glycemic status.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Carlos G. Santos-Gallego, Juan Antonio Requena-Ibanez, Rodolfo San Antonio, Alvaro Garcia-Ropero, Kiyotake Ishikawa, Shin Watanabe, Belen Picatoste, Ariana P. Vargas-Delgado, Eduardo J. Flores-Umanzor, Javier Sanz, Valentin Fuster, Juan J. Badimon
Summary: The study aimed to investigate the effect of empagliflozin on diastolic function in non-diabetic heart failure patients and the pathways causing diastolic dysfunction. Empagliflozin was found to improve diastolic function in non-diabetic HF patients, mitigates histological and molecular remodeling, and reduces both left ventricle and cardiomyocyte stiffness.
JACC-CARDIOVASCULAR IMAGING
(2021)
Article
Endocrinology & Metabolism
Odette S. Reifsnider, Pratik Pimple, Sarah Brand, Evelien Bergrath Washington, Sharash Shetty, Nihar R. Desai
Summary: The study found that for patients with type 2 diabetes, the use of empagliflozin as second-line treatment after metformin is a dominant strategy for US payers, associated with lower lifetime costs, improved quality-adjusted life years, and reductions in cardiovascular death rates and complication rates in patients with cardiovascular diseases.
DIABETES OBESITY & METABOLISM
(2022)
Article
Cardiac & Cardiovascular Systems
Diego Martinez-Lopez, Raquel Roldan-Montero, Fernando Garcia-Marques, Estefania Nunez, Inmaculada Jorge, Emilio Camafeita, Pablo Minguez, Santiago Rodriguez de Cordoba, Beatriz Lopez-Melgar, Enrique Lara-Pezzi, Antonio Fernandez-Ortiz, Borja Ibanez, Jose Manuel Valdivielso, Valentin Fuster, Jean-Baptiste Michel, Luis Miguel Blanco-Colio, Jesus Vazquez, Jose Luis Martin-Ventura
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2020)